Navigation Links
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
Date:6/19/2008

PHILADELPHIA, June 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved AVODART (dutasteride) in combination with tamsulosin for the treatment of symptomatic enlarged prostate, a disease that affects half of all men over 50 years old. The new indication reflects emerging research showing the combination of the two medicines treats the symptoms of enlarged prostate more effectively than either medicine alone.

"The combination of AVODART and tamsulosin at diagnosis allows doctors to simultaneously treat the patient's prostate on two fronts by reducing prostate size and rapidly improving symptoms," said Steven A. Kaplan, M.D., from Weill Cornell Medical College of Cornell University in New York City.

Common symptoms of enlarged prostate include nocturia, frequent and urgent urination, incomplete emptying, starting and stopping, and weak stream. If left untreated, enlarged prostate can lead to hospitalization for the inability to urinate or prostate surgery.

AVODART already had been approved by the FDA for the treatment of enlarged prostate to improve urinary symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of prostate-related surgery. Tamsulosin, an alpha-blocker, already had been indicated for the treatment of the signs and symptoms of enlarged prostate.

The FDA approval was based on two-year results of the CombAT (Combination of Avodart and Tamsulosin) study, one of the largest clinical trials to date of men with enlarged prostate. The CombAT study is the first long-term assessment of the combination of AVODART and an alpha-blocker. Study results were first presented in September 2007 at the 29th annual meeting of the Societe Internationale d'Urologie in Paris. The study was published in the February issue of the Journal of Urology.

The CombAT study results showed that combination therapy with AVODART and tamsulosi
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
3. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
4. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
5. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
6. Medicare Approves in Home Sleep Apnea Testing
7. 3SBio Inc. Approves Share Repurchase Program
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
10. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
11. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... decades as a manufacturing state, Ohio is positioning itself to ... jobs market. A recent Forbes article ranked Columbus, ... optimistic outlooks for other major Ohio cities. The magazine credits ... home to major research universities. Another contributing ...
... and TORONTO, Dec. 19, 2011 Generex Biotechnology ... scheduled to air a segment on the immunotherapeutic ... subsidiary, Antigen Express, Inc.  The segment is scheduled ... PST) today, Monday, December 19, 2011 (see promo ...
... Inc. announced today that it has entered into ... Biotech, Inc.  The agreement is based on Metamark,s ... specific proprietary cancer targets demonstrated to play a ... (Prognosis Determinants™). The collaboration will focus on the ...
Cached Biology Technology:Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 2Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 3Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 4Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 2Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 3Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 4Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech 2
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... the source of a unique rhythmic sound, recorded for ... is the Antarctic minke whale ( Balaenoptera bonaerensis ). ... 1960s who thought it sounded like a duck, the ... the Southern Ocean, but its source has remained a ... team of researchers deployed acoustic tags on two Antarctic ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... trials prove successful, a new discovery published in ... a major scientific leap toward human tissue regeneration and ... provide evidence to support a major paradigm shift in ... to a graft before implantation are the building blocks ...
... Cancer studies from Mercer University (Ga.) headline groundbreaking ... of Pharmaceutical Scientists, (AAPS) National Biotechnology Conference (NBC). The ... at the Hilton San Francisco Union Square. ... Cervical cancer is the second most common ...
Cached Biology News:Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6Yale scientists discover new method for engineering human tissue regeneration 2AAPS national biotechnology conference to highlight breakthrough cancer treatments 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
Biology Products: